Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer

Academic Article


  • The overall survival of patients with squamous cell cancer of the head and neck has not significantly improved over the past 2 decades. Preclinical studies suggest that combining a monoclonal antibody to the epidermal growth factor receptor with irradiation or chemotherapy agents active in squamous cell cancer of the head and neck could increase treatment efficacy. Completed phase I studies have shown these combinations to be both feasible and tolerable. Phase III studies are now beginning to establish firmly the efficacy of this innovative new approach.
  • Digital Object Identifier (doi)

    Author List

  • Wheeler RH; Spencer S; Buchsbaum D; Robert F
  • Start Page

  • 187
  • End Page

  • 190
  • Volume

  • 11
  • Issue

  • 3